Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1590750 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $19.88Day +1.90%Mkt cap $2.0B1Y +18.4%Off 52W high −42.0%Vol (1Y) 72.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest18.4% of sh out |
| Days to cover9.9d |
| 13F net flow (QoQ)+5.26% |
| Top-10 13F concentration49.8% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$70.9M |
| Earnings (TTM)-$360.6M |
| ROE−49.2% |
| Net margin−483.6% |
| Sales growth 3Y241.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−36.1% |
| 1Y+18.4% |
| 3Y+6.0% |
| 5Y+24.3% |
| Since incept. (ann.)+1.1% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)72.5% |
| Ann. volatility (3Y)66.8% |
| Sharpe (1Y)0.58 |
| Sharpe (3Y)0.36 |
| Max drawdown (1Y)−60.6% |
| Max drawdown (3Y)−60.6% |
| Beta (3Y vs SPY)1.79 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 15.4M | $301M | 14.92% | +6.9% |
| BlackRock, Inc. | 7.8M | $153M | 7.60% | +21.8% |
| Bellevue Group AG | 6.7M | $132M | 6.53% | +54.3% |
| STATE STREET CORP | 4.7M | $91M | 4.53% | +34.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | $82M | 4.04% | new |
| Fairmount Funds Management LLC | 3.9M | $77M | 3.80% | +0.0% |
| Venrock Adviser, LLC | 3.9M | $76M | 3.77% | +0.0% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.2M | $63M | 3.11% | −6.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 109.0% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 11,512,229 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | — | — | $141,000 | +95.8% |
| 2025-12-31 | 2026-02-26 | — | — | $132,000 | +83.3% |
| 2025-09-30 | 2025-11-05 | — | — | $70.6M | +81958.1% |
| 2025-06-30 | 2025-08-06 | — | — | $75,000 | +4.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
License 99% · Collaboration 1%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
